LadRx

LadRx EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of LadRx (LADX) as of Oct 18, 2026 is -0.02. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 0.02 — a change of -177.38% (lower).

EV/OCF

-0.02

YoY

-177.38%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of LadRx is 2024 -0.02 . EV/OCF (Enterprise Value to Operating Cash Flow) of LadRx was 2023 0.02 . It decreases by -177.38% lower compared to the previous year.

The LadRx EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023
0.02 USD
Jan 1, 2024
-0.02 USD
The LadRx EV/OCF history
YEAREV/OCFYoY
-0.02-177.38%
0.02-576.63%
-0.01+154.71%
-0.00-50.12%
-0.00-6.87%
-0.00+90.05%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LadRx Stock analysis

What does LadRx do? LadRx Corp, with ticker LADX and ISIN US2328287071, is a biotechnology company headquartered in Los Angeles, United States. The company has 2 employees and went public on November 10, 1986. Its website is http://www.cytrx.com/. LadRx Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's activities include the discovery, research, and clinical development of anti-cancer drug candidates. It focuses on aldoxorubicin, a modified version of doxorubicin, for clinical development. The company is involved in Phase III trials for aldoxorubicin as a treatment for soft tissue sarcoma in patients whose tumors have progressed after chemotherapy. Additionally, LadRx Corp is conducting Phase IIb trials for aldoxorubicin in small cell lung cancer, Phase II trials for HIV-related Kaposi's sarcoma, and Phase II trials for late-stage glioblastoma. The company also has Phase Ib trials combining aldoxorubicin with ifosfamide for soft tissue sarcoma and with gemcitabine for metastatic solid tumors. LadRx Corp is developing DK049, an anti-cancer drug conjugate utilizing its LADR technology, in pre-clinical stages. The company's website and public filings provide further details on its operations and clinical trials. LadRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LadRx stock

EV/OCF (Enterprise Value to Operating Cash Flow) of LadRx is -0.02 in 2024.

EV/OCF (Enterprise Value to Operating Cash Flow) of LadRx changed from 0.02 to -0.02, representing a -177.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) LadRx since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s LadRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LadRx

All Key Metrics — LadRx